Research Participants Should Have the Option to Be Notified of Results of Unknown but Potential Significance

The Food and Drug Administration (FDA) recently identified the need for further safety studies of gadolinium-based contrast agents (GBCAs) due to uncertainty regarding the effects of gadolinium ret...